The Medicines Patent Pool signs an agreement with 27 pharmaceutical companies in 11 countries to produce both raw ingredients and finished products of Merck & Co.'s Molnupiravir COVID-19 drug, which will be used in 105 low- and middle-income developing countries.
The Medicines Patent Pool sign an agreement with 27 pharmaceutical companies in 11 countries to produce both raw ingredients and finished products of molnupiravir licensed by Merck & Co. to supply 105 low- and middle-income developing countries.
The Medicines Patent Pool signs an agreement with 27 pharmaceutical companies in 11 countries to produce both raw ingredients and finished products of Merck&Co.'sMolnupiravir COVID-19drug,whichwillbe usedin 105 low- and middle-income developing countries.
